Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2014 · 10-Q
Revenue$0.00$0.00— vs Q3 2013 Net Income-$1.28M-$1.28MN/M vs Q3 2013 EPS Diluted-$0.02-$0.02N/M vs Q3 2013 Operating Income-$1,294,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,636,000N/M ended Mar 31, 2014 · filed May 15, 2014 · 45 d after period end